Collectively, these findings suggest that AKR1A1 lactylation plays a central role in the metabolism–immunity regulatory axis of osteoporosis, and highlight its potential as an early molecular biomarker and therapeutic target. This evidence concerns the gene AKR1A1 and osteoporosis.